Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Next Previous
Trial Profile

A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy Versus Standard of Care in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Aug 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dostarlimab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Colon cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AZUR-2
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 20 Jan 2024 Trial deisgn presented at the 2024 Gastrointestinal Cancers Symposium
  • 02 Jan 2024 Planned End Date changed from 31 Jan 2031 to 15 Dec 2028.
  • 02 Jan 2024 Planned primary completion date changed from 23 Jan 2029 to 15 Dec 2028.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top